Literature DB >> 28673637

Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure.

Sabashini K Ramchand1, Ego Seeman2, Xiao-Fang Wang3, Ali Ghasem-Zadeh3, Prudence A Francis4, Evangeline J Ponnusamy4, Michele S Bardin5, Minh Bui6, Roger Zebaze3, Jeffrey D Zajac3, Mathis Grossmann3.   

Abstract

BACKGROUND: In premenopausal women with early estrogen-receptor-positive breast cancer, combined ovarian suppression and aromatase inhibition reduce estradiol production precipitously. The resulting unbalanced and rapid bone remodelling replaces older bone with less bone that is less fully mineralized. We hypothesized that these changes result in severe microstructural deterioration and reduced matrix mineralization density.
METHODS: Images of the distal radius and distal tibia were acquired using high-resolution peripheral quantitative computed tomography in a cross-sectional study of 27 premenopausal women, mean age 43.3years (range 30.4 to 53.7) with early breast cancer made estradiol deficient for 17months (range 6-120) using ovarian suppression and aromatase inhibition, 42 healthy age-matched premenopausal and 35 postmenopausal controls, mean age 62.6years (range 60.2 to 65.5). Cortical and trabecular microstructure were quantified using Strax software.
RESULTS: Compared with premenopausal controls, the women with breast cancer had 0.75 SD (95% CI 0.21 to 1.29) lower distal radial trabecular bone volume due to 1.29 SD (0.71 to 1.87) fewer trabeculae. Cortical porosity was 1.25 SD (0.59 to 1.91) higher but cortical thickness was not reduced. Compared with postmenopausal controls 20years older, cases had comparable or lower trabecular bone volume and comparable cortical porosity and thickness. Matrix mineral density was 1.56 SD (0.90 to 2.22) lower than in premenopausal controls and 2.17 SD (1.50 to 2.84) lower than in postmenopausal controls. Results at the tibia were similar.
CONCLUSION: The severe cortical porosity and trabecular deterioration associated with estradiol depletion and the longevity of premenopausal women with early breast cancer treated with endocrine therapy provide a compelling rationale to investigate the efficacy of antiresorptive therapy initiated at the time of breast cancer treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aromatase inhibition; Bone structure; Breast cancer; Estradiol depletion; Ovarian suppression; Premenopausal

Mesh:

Substances:

Year:  2017        PMID: 28673637     DOI: 10.1016/j.bone.2017.06.024

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  2 in total

Review 1.  The skeletal impact of cancer therapies.

Authors:  Lucia Bedatsova; Matthew T Drake
Journal:  Br J Clin Pharmacol       Date:  2019-02-21       Impact factor: 4.335

2.  Effect of tamoxifen with or without gonadotropin-releasing hormone analog on DXA values in women with breast cancer.

Authors:  Eun Heui Kim; Yun Kyung Jeon; Kyoungjune Pak; Taewoo Kang; Kyung-Eun Kim; Seong-Jang Kim; In-Joo Kim; Keunyoung Kim
Journal:  Sci Rep       Date:  2021-02-09       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.